September 21-23, 2010 • New York City

More information on the 2010 event to be announced shortly.
Save the date in your Microsoft Outlook Calendar

Registration Individual Registration Company 2010 Hotel Information 2010 Schedule Early Bird Discount $400 (exp. 4/30/10) Individual Registration: Reg. $1995 Company Registration: Reg. $1795 3 or more attendees, each Cancellation Policy Conference Sponsorship Brochure 2009 Attending Companies 2009 Schedule

Interested in presenting at a Windhover conference? Submit your idea here

Thank you to all the attendees, speakers and sponsors who helped make PSA 2009 a resounding success!

NEW PROGRAM and VENUE FOR 2009!

• 1:1 interview with Schering-Plough's CEO Fred Hassan
• 1:1 fireside chat with GSK's Head of R & D, Moncef Slaoui
• 11+ networking opportunities with the most senior level executives in the biopharma business
• 3 FREE pre-conference workshops
• 27+ strategies from pharma heads of R & D, BD, CFOs, CEOs and corporate VCs
• 25+ deal case studies, biotech investing, M&A, health reform, and more! Complete schedule available here.

WHY ATTEND PSA?

Simple. Meet the most important people in the business.

Beyond the basics! Windhover is proud to present the ONLY conference that delivers 100% case studies by CEOs and senior executives in the industry. Don’t miss insight from the following strategists, including:

Fred Hassan CEO Schering-Plough Corporation Frank D’Amelio CFO Pfizer David Mott General Partner New Enterprise Associates Former MedImmune CEO Elliott Sigal, MD, PhD EVP, CSO, President, Research and Development Bristol-Myers Squibb Martin MacKay President of Pfizer Global Research & Development Pfizer Michael Diem, MD Partner SR One/Glaxosmithkline Vincent Aurentz Executive Vice President, Portfolio Development Merck Serono

Mervyn Turner Chief Strategy Officer and SVP, WW Licensing & External Research Merck and Company Thomas Hofstaetter SVP, Corporate Business Development Wyeth Jean-Luc Belingard Chairman & CEO Ipsen Judith Hills Vice President, Asia Pacific, Japan and Emerging Markets R&D Glaxosmithkline Andrew Dillon CEO National Institute for Health and Clinical Excellence NICE Dr. Lauren Silverman Novartis Option Fund Peter Mueller, PhD Executive Vice President, Global Research and Development, and Chief Scientific Officer Vertex Pharmaceuticals

Benchmark your corporate strategies against the best and the brightest.

Can You Be Big and Small at Once?

For at least two decades now, Big Pharma has believed in the value of big. But they’ve also seen its downside: bureaucratic paralysis, the burden of growing a substantial top-line, cultural stagnation. And so a number of companies are now trying to have their cake and eat it, too: adding capabilities (through acquisitions) and diversifications while creating therapeutically- or market-focused units capable of making and executing their own investment decisions independent of the mother ship). This way they’ll have the advantages of being big (the financial strength to survive major research and commercial blows, the infrastructure to globally develop and commercialize new opportunities) and small (speed, focus and entrepreneurial excitement). The 19th annual PSA will explore the implications and inherent contradictions of this new bifurcated strategy, how and why companies are pursuing it (or not pursuing it) and its likely effects on biotech and on dealmaking in general.

Who will you meet?

• Meet your potential partner and find out how to approach them Meet your potential partner and find out how to approach them
• Understand externalization models and see if your approach fits your potential partner's positioning
• Benchmark your dealmaking strategy against what your competitors are doing and why
• Learn the deal values and deal specifics that let you calibrate deal-making metrics

What your colleagues and competitors have to say about Pharmaceutical Strategic Alliances:

"Overall, I was pleasantly surprised. It was an excellent meeting and exceeded my expectations because of the quality of attendees." "I appreciate Windhover conferences. Your organization is one of the few that is trying to understand the pharma/biotech industry in a strategic context." "I attend every year. The content is always engaging." "One of the 'most attended' conferences, as always." "One of the conferences that I learn something of value." "It was very good, the presentations and networking opportunities were excellent." "Definitely worthwhile. Speakers focused on topics and insights, not on company promotion." "Excellent topic coverage, as well as representation of speakers." "The entire agenda is well thought-out and covers several very pertinent topics." "Great chance to network with leading business development professionals in the industry and share collaboration ideas." "A good review of what is going on at the pharma and biotech industries with a brilliant strategic analysis. Excellent selection of speakers and participants at the roundtable discussions."